Conjugated psychotropic drugs and uses thereof

Abstract

Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and / or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and / or to exert an anti-proliferative activity.

Description

RELATED APPLICATIONS [0001] This Application is a divisional of pending U.S. patent application Ser. No. 10 / 808,541 filed Mar. 25, 2004, which is a continuation-in-part of PCT Patent Application No. PCT / IL02 / 00795 filed Sep. 29, 2002, which claims the benefit of U.S. Provisional Patent Application No. 60 / 324,936, filed Sep. 27, 2001. The contents of the above Applications are all incorporated by reference.FIELD AND BACKGROUND OF THE INVENTION [0002] The present invention relates to novel chemical conjugates of psychotropic drugs and organic acids, and uses thereof. More particularly, the present invention relates to novel chemical conjugates of psychotropic drugs (which may also have anti-proliferative activity and / or chemosensitization activity), and organic acids selected so as to reduce side effects induced by the psychotropic drugs and / or so as to exert an anti-proliferative activity, and uses thereof in the treatment of psychotropic and / or proliferative disorders and diseases a...

AI Technical Summary

Benefits of technology

[0024] It is shown herein that such chemical conjugates of psychotropic drugs are characterized by minimized adverse side effects (e.g., extrapyramidal symptoms), enhanced psychotropic therapeutic activity and anti-proliferative activity and by chemosensitization activity. It is further shown herein that such chemical conjugates unexpectedly provide synergistic effects as compared to their parent compounds both with respect to their therapeutic effects and with respect to the minimization of side effects.

[0025] Thus, according to one aspect of the present invention there is provided a chemical conjugate comprising a first chemical moiety covalently linked to a second chemical moiety, wherein the first chemical moiety is a psychotropic drug residue and further wherein the second chemical moiety is an organic acid residue that is selected so as to reduce side effects induced by the psychotropic drug when the psychotropic drug is administered per se and / or to exert anti-proliferative activity.

[0057] The present invention successfully addresses the shortcomings of the presently known configurations by providing new and potent chemical conjugates of psychotropic drugs that induce minimized adverse side effects for the treatment and prevention of psychotropic and / or proliferative disorders and diseases and for use as chemosensitizers.

Problems solved by technology

Unfortunately, the administration of psychotropic drugs is typically associated with adverse side effects, such as seizures, headaches, fatigue, hyperactivity, dizziness, and many more, which severely limit their use.

However, the administration of currently available neuroleptic drugs is frequently associated with adverse side effects.

However, the administration thereof involves other side effects such as increase of body weight, mood disturbances, sexual disfunction, sedation, orthostatic hypotension, hypersalivation, lowered seizure threshold and, in particular, agranulocytosis.

However, U.S. Pat. No. 6,197,764 fails to disclose such advantageous conjugates that include other anti-psychotic agents and is further limited to conjugates including long-chain fatty acids.

Nevertheless, such conjugates are aimed mainly at facilitating the brain penetration of the drug and are not designed to actively reduce or prevent side effects.

However, while some of the claimed fluoro-substituted phenothiazine derivatives of U.S. Pat. No. 3,966,930 include an acyl radical that has 1-17 carbon atoms in its chain, the experimental data is limited to phenothiazine derivatives that include only acyl radicals derived from either oxalic acid or maleic acid (i.e., organic acids that include 2 and 4 carbon atoms, respectively).

Previous studies have already suggested that GABA agonists can interfere with other brain neurotransmitters and, in particular, with the dopamine system.

The use of GABA agonists is limited since they include hydrophilic functional groups (e.g., a free carboxylic acid group and a free amino group) and therefore do not readily cross the blood brain barrier (BBB).

However, although the teachings of WO 02 / 43652 are highly advantageous, particularly with respect to the anti-proliferative and chemosensitization activity of psychotropic agents in the treatment of MDR cancer, the use of these psychotropic agents is highly limited by the adverse side effects induced thereby.

Images